Market Overview:
The global pulmonary embolism drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of pulmonary embolism, rising awareness about the disease, and technological advancements in the field of pulmonary embolism drugs. Based on type, the global pulmonary embolism drug market is segmented into DS-9231, DS-1040, TRX-1 and others. The DS-9231 segment is expected to account for a major share of the global market due to its high efficacy and safety profile. Based on application, the hospital segment dominates this market owing to increased incidence rates of pulmonary embolism in hospitals as compared to other settings such as clinics or home care settings.
Product Definition:
Pulmonary embolism is a blockage of an artery in the lungs. It can be caused by a blood clot that has traveled from another part of the body, such as the leg. Pulmonary embolism can also be caused by other materials, such as air bubbles or fat.
DS-9231:
DS-9231 is a novel oral drug that belongs to a new class of drugs called thrombolytic agents. It is currently in phase II clinical trials and has shown positive results so far. DS-9231 has the potential to be the first oral drug with high efficacy and favorable safety/toxicity profile for pulmonary embolism (PE) treatment, which would make it an ideal candidate for approval by regulatory bodies worldwide.
DS-1040:
DS-1040 is a blood thinner and it works by reducing the formation of new blood clots. The drug was approved in Europe in 2010 and in the U.S. in 2011 for treatment of pulmonary embolism, which is used as a preventative measure to avoid life-threatening complications due to blood clotting.
Application Insights:
Based on the application, the global pulmonary embolism drug market is segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to factors such as availability of advanced healthcare facilities along with highly skilled personnel at a relatively low cost. Moreover, an increase in prevalence of diseases that may lead to PE and growing awareness among patients about early diagnosis are some other factors responsible for its large share.
The clinic segment is expected to grow at a faster rate than that observed for hospital during the forecast period due to increasing number of clinics across various regions coupled with rising awareness regarding effective treatment methods for various diseases including PE. In addition, these centers provide better diagnostic options leading to higher adoption rates by patients seeking medical assistance for different conditions related to their lungs such as cough or shortness of breath etc., which further boosts growth prospects over forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing incidence of PEs and rising geriatric population. In addition, high adoption of TRX-1 and other drugs for treatment of pulmonary embolism is also one factor responsible for maintaining dominance of this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving healthcare infrastructure, economic development, and rising awareness about early diagnosis & treatment options for pulmonary embolism. Moreover, availability of generic drugs at a low cost will further boost regional growth during the estimated time span from 2018 to 2030 (see Table 1).
In 2016, an estimated 3 million people were affected by Pulmonary Embolism (PE) in China alone which accounts for approximately 0.6% - 1% prevalence rate annually among adults aged 30 years and above [5].
Growth Factors:
- Increasing incidence of pulmonary embolism
- Growing awareness about the symptoms and risk factors of pulmonary embolism
- Rising demand for effective and safe drugs for the treatment of pulmonary embolism
- Technological advancements in drug development process
- Growing number of clinical studies on new drugs for the treatment of pulmonary embolism
Scope Of The Report
Report Attributes
Report Details
Report Title
Pulmonary Embolism Drug Market Research Report
By Type
DS-9231, DS-1040, TRX-1, Others
By Application
Hospital, Clinic, Others
By Companies
Accu-Break Pharmaceuticals, Inc., Dong-A Socio Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech, Inc., Verseon Corp
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Pulmonary Embolism Drug Market Report Segments:
The global Pulmonary Embolism Drug market is segmented on the basis of:
Types
DS-9231, DS-1040, TRX-1, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Accu-Break Pharmaceuticals, Inc.
- Dong-A Socio Holdings Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Verseon Corp
Highlights of The Pulmonary Embolism Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- DS-9231
- DS-1040
- TRX-1
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pulmonary Embolism Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A pulmonary embolism drug is a medication that helps to prevent or treat a pulmonary embolism. Pulmonary embolism drugs can be used to prevent an embolic episode from occurring, or to help treat an existing episode.
Some of the major players in the pulmonary embolism drug market are Accu-Break Pharmaceuticals, Inc., Dong-A Socio Holdings Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech, Inc., Verseon Corp.
The pulmonary embolism drug market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pulmonary Embolism Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pulmonary Embolism Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pulmonary Embolism Drug Market - Supply Chain
4.5. Global Pulmonary Embolism Drug Market Forecast
4.5.1. Pulmonary Embolism Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pulmonary Embolism Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pulmonary Embolism Drug Market Absolute $ Opportunity
5. Global Pulmonary Embolism Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pulmonary Embolism Drug Market Size and Volume Forecast by Type
5.3.1. DS-9231
5.3.2. DS-1040
5.3.3. TRX-1
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pulmonary Embolism Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pulmonary Embolism Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pulmonary Embolism Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pulmonary Embolism Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pulmonary Embolism Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pulmonary Embolism Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pulmonary Embolism Drug Demand Share Forecast, 2019-2026
9. North America Pulmonary Embolism Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pulmonary Embolism Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pulmonary Embolism Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pulmonary Embolism Drug Market Size and Volume Forecast by Type
9.7.1. DS-9231
9.7.2. DS-1040
9.7.3. TRX-1
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pulmonary Embolism Drug Demand Share Forecast, 2019-2026
10. Latin America Pulmonary Embolism Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pulmonary Embolism Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pulmonary Embolism Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pulmonary Embolism Drug Market Size and Volume Forecast by Type
10.7.1. DS-9231
10.7.2. DS-1040
10.7.3. TRX-1
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pulmonary Embolism Drug Demand Share Forecast, 2019-2026
11. Europe Pulmonary Embolism Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pulmonary Embolism Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pulmonary Embolism Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pulmonary Embolism Drug Market Size and Volume Forecast by Type
11.7.1. DS-9231
11.7.2. DS-1040
11.7.3. TRX-1
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pulmonary Embolism Drug Demand Share, 2019-2026
12. Asia Pacific Pulmonary Embolism Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pulmonary Embolism Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pulmonary Embolism Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pulmonary Embolism Drug Market Size and Volume Forecast by Type
12.7.1. DS-9231
12.7.2. DS-1040
12.7.3. TRX-1
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pulmonary Embolism Drug Demand Share, 2019-2026
13. Middle East & Africa Pulmonary Embolism Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pulmonary Embolism Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pulmonary Embolism Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pulmonary Embolism Drug Market Size and Volume Forecast by Type
13.7.1. DS-9231
13.7.2. DS-1040
13.7.3. TRX-1
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pulmonary Embolism Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pulmonary Embolism Drug Market: Market Share Analysis
14.2. Pulmonary Embolism Drug Distributors and Customers
14.3. Pulmonary Embolism Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Accu-Break Pharmaceuticals, Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Dong-A Socio Holdings Co. Ltd.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-La Roche Ltd.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Genentech, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Verseon Corp
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
